US Stock MarketDetailed Quotes

LCTX Lineage Cell Therapeutics

Watchlist
  • 1.020
  • -0.100-8.93%
Close Jul 24 16:00 ET
  • 1.010
  • -0.010-0.98%
Post 16:23 ET
192.60MMarket Cap-7846P/E (TTM)

Lineage Cell Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Lineage Cell Therapeutics Earnings Date

Currency: USD

Period

Q1 FY2024 Earnings

May 9, 2024

Revenue(YoY)

1.44M

-39.48%
EPS(YoY)

-0.04

-33.33%
Analyst Rating

Strong Buy

Jun 30, 2024

Lineage Cell Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 1.304M--
--2024/Q2-- / 786.000K--
May 9, 20242024/Q11.444M / 1.360M--
Mar 7, 20242023/Q42.118M / 2.844M--
Nov 9, 20232023/Q31.246M / 2.650M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 1.304M--
--2024/Q2-- / 786.000K--
May 9, 20242024/Q11.444M / 1.360M--
Mar 7, 20242023/Q42.118M / 2.844M--
Nov 9, 20232023/Q31.246M / 2.650M--

Unlock Free Earnings Estimates

Lineage Cell Therapeutics Earnings Reports

  • Lineage Cell Therapeutics | 10-Q: Quarterly report

    May 9 17:03 ET

  • Lineage Cell Therapeutics | 10-K: Annual report

    Mar 7 22:16 ET

  • Lineage Cell Therapeutics: Q3 2023 Earnings Report

    Nov 9, 2023 16:15 ET

  • Lineage Cell Therapeutics | 10-Q: Q2 2023 Earnings Report

    Aug 10, 2023 16:16 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jun 30, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    %Chg